TargetBeta
CDK2
cyclin dependent kinase 2 · Cyclin dependent kinases
10 programs in company-led studies act on CDK2, from 10 companies: 2 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (6 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| culmerciclib | Sino Biopharmaceutical | phase 3 | 115 running | CDK4, CDK6 | the company's pipeline |
| CDK2 Inhibitor INCB123667rule | Incyte | phase 3 | 75 running | – | NCIt |
| vustanaciclib | Regor Pharmaceuticals | phase 2 | 33 running | CDK4, CDK6 | a judged reading |
| tegtociclib | Pfizer | phase 2 | 42 running | – | the company's pipeline |
| CDK2 Inhibitor AVZO-021rule | Avenzo Therapeutics | phase 2 | 22 running | – | NCIt |
| CDK2 Inhibitor ECI830 | Novartis | phase 2 | 11 running | – | the company's pipeline |
| CDK2 Degrader BG-75098rule | BeOne Medicines | phase 1 | 11 running | – | NCIt |
| CG-7321rule | Chengdu Cynogen Bio-pharmaceutical Tech. | phase 1 | 11 running | CDK4 | the studies' text |
| nkt5097 cdk2rule | NiKang Therapeutics | phase 1 | 11 running | CDK4 | the studies' text |
| ZE94-0605rule | Eilean Therapeutics | phase 1 | 11 running | – | the studies' text |
Conditions their studies are in
- Breast Neoplasms, 5 programs
- Small Cell Lung Carcinoma, 2 programs
- Carcinoma, Ovarian Epithelial, 1 program
- Hepatic Insufficiency, 1 program
- Kidney Failure, Chronic, 1 program
- Liposarcoma, 1 program
- Neoplasm Metastasis, 1 program
- Ovarian Neoplasms, 1 program
- Triple Negative Breast Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026culmerciclib · Sino Biopharmaceutical · phase 3 · NCT05780567
- Dec 30, 2026vustanaciclib · Regor Pharmaceuticals · phase 2 · NCT06299124
- Dec 31, 2026tegtociclib · Pfizer · phase 2 · NCT04553133
- Jan 4, 2027CDK2 Inhibitor INCB123667 · Incyte · phase 3 · NCT07559396
- Apr 2027CG-7321 · Chengdu Cynogen Bio-pharmaceutical Tech. · phase 1 · NCT07923214
- Jul 31, 2027nkt5097 cdk2 · NiKang Therapeutics · phase 1 · NCT07029399
- Jan 2028ZE94-0605 · Eilean Therapeutics · phase 1 · NCT07524140
- Jan 31, 2028CDK2 Inhibitor AVZO-021 · Avenzo Therapeutics · phase 2 · NCT05867251
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.